BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marathe BM, Mostafa HH, Vogel P, Pascua PNQ, Jones JC, Russell CJ, Webby RJ, Govorkova EA. A pharmacologically immunosuppressed mouse model for assessing influenza B virus pathogenicity and oseltamivir treatment. Antiviral Res 2017;148:20-31. [PMID: 29100887 DOI: 10.1016/j.antiviral.2017.10.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Zeng J, Wan X, Liu T, Xiong Y, Xiang G, Peng Y, Zhu R, Zhou Y, Liu C. Chlorogenic acid ameliorates Klebsiella pneumoniae-induced pneumonia in immunosuppressed mice via inhibiting the activation of NLRP3 inflammasomes. Food Funct 2021;12:9466-75. [PMID: 34473137 DOI: 10.1039/d0fo03185b] [Reference Citation Analysis]
2 Marathe BM, Asthagiri Arunkumar G, Vogel P, Pascua PNQ, Jones J, Webby RJ, Krammer F, Govorkova EA. Monoclonal Antibody Therapy Protects Pharmacologically Immunosuppressed Mice from Lethal Infection with Influenza B Virus. Antimicrob Agents Chemother 2020;64:e00284-20. [PMID: 32631823 DOI: 10.1128/AAC.00284-20] [Reference Citation Analysis]
3 Smith AM. Host-pathogen kinetics during influenza infection and coinfection: insights from predictive modeling. Immunol Rev 2018;285:97-112. [PMID: 30129197 DOI: 10.1111/imr.12692] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 12.3] [Reference Citation Analysis]
4 Sahu U, Biswas D, Prajapati VK, Singh AK, Samant M, Khare P. Interleukin-17-A multifaceted cytokine in viral infections. J Cell Physiol 2021. [PMID: 34133758 DOI: 10.1002/jcp.30471] [Reference Citation Analysis]
5 Esmagambetov IB, Shcheblyakov DV, Egorova DA, Voronina OL, Derkaev AA, Voronina DV, Popova O, Ryabova EI, Shcherbinin DN, Aksenova EI, Semenov AN, Kunda MS, Ryzhova NN, Zubkova OV, Tukhvatulin AI, Logunov DY, Naroditsky BS, Borisevich SV, Gintsburg AL. Nanobodies Are Potential Therapeutic Agents for the Ebola Virus Infection. Acta Naturae 2021;13:53-63. [DOI: 10.32607/actanaturae.11487] [Reference Citation Analysis]
6 Pascua PNQ, Marathe BM, Vogel P, Webby RJ, Govorkova EA. Optimizing T-705 (favipiravir) treatment of severe influenza B virus infection in the immunocompromised mouse model. J Antimicrob Chemother 2019;74:1333-41. [PMID: 30715325 DOI: 10.1093/jac/dky560] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Rattan A, White CL, Nelson S, Eismann M, Padilla-quirarte H, Glover MA, Dileepan T, Marathe BM, Govorkova EA, Webby RJ, Richards KA, Sant AJ. Development of a Mouse Model to Explore CD4 T Cell Specificity, Phenotype, and Recruitment to the Lung after Influenza B Infection. Pathogens 2022;11:251. [DOI: 10.3390/pathogens11020251] [Reference Citation Analysis]
8 Myers MA, Smith AP, Lane LC, Moquin DJ, Aogo R, Woolard S, Thomas P, Vogel P, Smith AM. Dynamically linking influenza virus infection kinetics, lung injury, inflammation, and disease severity. Elife 2021;10:e68864. [PMID: 34282728 DOI: 10.7554/eLife.68864] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Antalis E, Spathis A, Kottaridi C, Kossyvakis A, Pastellas K, Tsakalos K, Mentis A, Kroupis C, Tsiodras S. Th17 serum cytokines in relation to laboratory-confirmed respiratory viral infection: A pilot study. J Med Virol 2019;91:963-71. [PMID: 30715745 DOI: 10.1002/jmv.25406] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
10 Zaraket H, Hurt AC, Clinch B, Barr I, Lee N. Burden of influenza B virus infection and considerations for clinical management. Antiviral Res 2021;185:104970. [PMID: 33159999 DOI: 10.1016/j.antiviral.2020.104970] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]